Saturday, August 22, 2026
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 17, 2026

AbbVie Down Since Q4 Earnings Report: How to Play the Stock

View original at finance.yahoo.com
AbbVie Down Since Q4 Earnings Report: How to Play the Stock AbbVie (ABBV) stock felt some downward pressure despite reporting better-than-expected fourth-quarter results on Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Phase III data with Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus expected in 2026

    80% confidence
  • Oncology pipeline is robust with several study readouts and initiations expected this year

    80% confidence
  • Vyalev expected to achieve blockbuster status in 2026, with sales expected to ramp up substantially in the United States

    80% confidence
  • No significant LOE (loss of exclusivity) events for the rest of this decade

    80% confidence
  • Expects high single-digit revenue growth through 2029

    80% confidence
  • Next wave of potential approvals in Rinvoq could add roughly $2 billion to peak-year sales for the product

    80% confidence
  • Total revenues expected to rise approximately 9.5% in 2026

    80% confidence
  • Expects low single-digit pricing headwind for both Skyrizi and Rinvoq in 2026 and over the next few years

    80% confidence
  • Aesthetics category growth expected to remain challenged in 2026

    80% confidence
  • Combined Skyrizi and Rinvoq sales expected to exceed $31 billion in 2026

    80% confidence
  • Global aesthetics sales expected to be $5 billion in 2026, flat from 2025 levels

    80% confidence
  • Rinvoq could be approved for two indications — vitiligo and alopecia areata in 2026

    80% confidence
  • AbbVie stock is a Zacks Rank #3 (Hold)

    80% confidence

Data points we hold from this source

AbbVie Inc. · neuroscience revenue10.8 billion_USD
AbbVie Inc. · oncology revenue6.6 billion_USD
AbbVie Inc. · acquisition spending5 billion_USD